Kisqali

This year marks the congress’s 50th anniversary, with the theme: Many journeys. One global community

The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

The drug is already approved in the UK to treat advanced cases of the disease

Approximately 70% of breast cancer cases are diagnosed in the early stages of the disease

Approximately 70% of all breast cancer patients have HR-positive/HER2-negative disease

The drug is already approved for certain cases of advanced or metastatic breast cancer

Researchers discovered that targeting the CDK6 protein could make tumour cells vulnerable to treatment

The company has started a strategic review of Sandoz as sales drop 20% in ‘challenging’ US market

Novartis’ Kisqali plus letrozole offers more than a year survival benefit for postmenopausal women with HR+/HER2 advanced breast cancer

mCRPC patients treated with Lu-PSMA-617 plus best standard of care achieved a 38% reduction in the risk of death

Data shows the ‘longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients’

Core operating income increased by 11%, profits from net income drop